ALERE T2-ISO Influenza Clia Waived Molecular Rapid Flu Inet 7715

( Brand: Alere ), ( Manufacturer Part Number: T2-ISO )

Review ALERE Influenza Clia Waived Molecular Rapid Flu Test Inet Sn

The T2-ISO Alere Influenza CLIA Waived Molecular Rapid Flu INET 7715 is a cutting-edge diagnostic tool designed for the rapid detection of influenza A and B viruses. This instrument employs real-time PCR technology, which is a highly sensitive and specific method for identifying nucleic acid sequences, ensuring accurate and reliable results.

The T2-ISO Alere Influenza CLIA Waived Molecular Rapid Flu INET 7715 operates on a simple-to-use, compact device. It requires minimal hands-on time, making it an ideal solution for high-volume clinical settings such as hospitals, clinics, and emergency departments. The instrument's compact design allows for easy transportation between different departments within a healthcare facility, maximizing efficiency and reducing the need for sample transport.

The test process with the T2-ISO Alere Influenza CLIA Waived Molecular Rapid Flu INET 7715 is straightforward. Samples, such as nasal swabs or nasopharyngeal aspirates, are collected from patients and then loaded into the device. The instrument uses a proprietary cartridge that contains all the necessary reagents and primers for the PCR reaction. Once the sample is loaded, the instrument performs the necessary steps to extract the viral RNA, amplify it, and detect the presence of influenza A and B viruses. Results are typically available within 30 minutes, providing healthcare providers with timely information to initiate appropriate treatment and infection control measures.

The T2-ISO Alere Influenza CLIA Waived Molecular Rapid Flu INET 7715 is an valuable asset in the fight against seasonal and pandemic influenza. Its high sensitivity and specificity, rapid turnaround time, and ease of use make it a reliable and efficient diagnostic tool for detecting influenza infections. This instrument can help healthcare providers make informed decisions, improve patient care, and contribute to disease control and prevention efforts.

1. Rapid Results: This test provides results within 15-20 minutes, which is faster compared to traditional flu tests that can take up to 2 hours. This quick turnaround time can help in early detection and treatment of the flu.

2. High Sensitivity and Specificity: The test has a high sensitivity and specificity, which means it can accurately detect influenza A and B viruses. This ensures that patients receive the correct diagnosis and treatment.

3. CLIA Waived: The test is CLIA waived, which means it can be performed in a variety of settings, including physician offices, urgent care centers, and clinical laboratories. This increases accessibility to the test.

4. Automated and Easy to Use: The test is automated and easy to use, which reduces the risk of human error. It requires minimal training to operate, making it suitable for healthcare providers with different levels of experience.

1. Cost: The test can be expensive compared to other flu diagnostic methods. The cost may be a concern for some healthcare providers, especially those operating on a tight budget.

2. Limited Detection: The test can only detect influenza A and B viruses. It does not detect other respiratory viruses, such as rhinovirus or coronavirus.

3. Limited Availability: The test may not be widely available in all areas, which could limit its use in certain healthcare settings.

The T2-ISO Alere Influenza CLIA Waived Molecular Rapid Flu INET 7715 is a useful tool for diagnosing influenza A and B viruses quickly and accurately. Its advantages, such as rapid results, high sensitivity and specificity, and ease of use, make it a valuable addition to any healthcare setting. However, its cost and limited detection capabilities should be considered before making a purchase. If the benefits of the test outweigh the drawbacks for your healthcare setting, it could be a worthwhile investment. It is recommended to consult with your healthcare provider or laboratory supplier to determine if this test is the best fit for your needs.

Details:

Power adapter and other accessories not included. Is the refurbishing and liquidation for one of countries leading leasing agents computer equipment. Includes only what is shown.

Alere I influenza a b clia waived molecular rapid flu test T2-ISO inet sn thumbnails to - unit powers on and begins loading, however then shows application has critical error.

You can through messages. Please feel free to ask any questions or make an offer.

Item has some light signs of use. In an effort to keep their equipment up date, most large corporations turn perfectly good computer at the end of lease. See images for items detailed condition.

No further testing or troubleshooting performed.

Reboot required. There is a tear in the clear screen cover.

Selling as is.

specifications labequipi:

• brand: Alere
• mpn: T2-iso

Offer labequipi:

• best offer: true
• bids: 0
• Sold: 0
• quantity: 1
• Started: September 13, 2018, 10:17 am

Returns labequipi:

• policy: returns accepted
• time: 30 Days
• paid by: Buyer
• type: Money back or replacement buyers choice

General labequipi:

• business industrial > healthcare life science lab equipment business industrial > other lab equipment
• condition: For parts or not working
• in stock: Yes

Ratings:

1. The best seller! 09-13-18
2. Great transaction. Thank you! 09-11-18
3. Exactly as described. Thank you!! 09-11-18
4. Very fast and easy transactions 09-10-18
5. great ! 09-07-18

Shipping labequipi:

• cost: $0.0
• type: Flat
• handling: 1 days

Payments labequipi:

• PayPal

Seller labequipi:

• city: Framingham, Massachusetts
• zipcode: 01701

Alere 7715 Is Similar To:

• 13-454 Alere Cholestech Ldx Cholesterol Test Monitoring System (41.9% similar) The machine was used in a lab setting. It is in perfect working condition. This for 1 Alere chillest LDC analyzer machine...(May 26th, 2018)
• Alere Eq002001 I Influenza Rapid Test Analyzer (51.3% similar) Functional condition: untested, no power adapter unable to test further...(May 12th, 2026)